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ABSTRACT  
Two simple, precise and economical UV methods have been developed for the estimation of Darunavir ethanolate (DRV) in bulk and pharmaceutical 
dosage form. Method A is Absorbance maxima method, which is based on measurement of absorption at maximum wavelength, 266 nm. Method B is 
area under curve (AUC), in the wavelength range of 255-275 nm. Linearity for detector response was observed in the concentration range of 3-18 
μg/ml for the both methods. The developed method was validated with respect to linearity, accuracy (recovery), precision and specificity. The 
accuracy of the methods was assessed by recovery studies and was found to be 100.07% and 99.58% for Method A and Method B respectively. The 
results were validated statistically as per ICH Q2 R1 guidelines and were found to be satisfactory. The proposed methods were successfully applied 
for the determination of DRV in tablet dosage form.  
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INTRODUCTION 
Darunavir ethanolate (DRV) [Fig.1] is an antiviral drug and inhibitor 
of the human immunodeficiency virus (HIV) protease in adults and 
children 6 years of age and older. It was approved by the Food and 
Drug Administration (FDA) on June 23, 2006. Chemically it is 
[(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]- 2-
hydroxy-1- (phenyl methyl)propyl]-carbamic acid (3R,3aS,6aR) 
hexahydrofuro [2,3-b] furan-3-yl ester monoethanolate. DRV, a 
second generation protease inhibitor, is discovered to overcome the 
problems with early protease inhibitor (PIs) like severe side effects 
and drug toxicities, require a high therapeutic dose, are costly to 
manufacture, and show a disturbing susceptibility to drug resistant 
mutations. DRV is used with ritonavir and other medications to treat 
HIV. It works by slowing the spread of HIV in the body.   
DRV selectively inhibits the cleavage of HIV-1 encoded Gag- Pol 
polyproteins in infected cells, thereby preventing the formation of 
mature virus particles. DRV was designed to form robust 
interactions with the protease enzyme from many strains of HIV, 
including strains from treatment-experienced patients with 
multiple resistance mutations to PIs. It blocks HIV protease, an 
enzyme which is needed for HIV to multiply. HIV infection 
destroys CD4 (T) cells, which are important to the immune 
system. The immune system helps fight infection. Reducing the 
amount of HIV and increasing the CD4 (T) cell count may 
improve your immune system and, thus, reduce the risk of death 
or infections that can happen when your immune system is weak 
(opportunistic infections).  
The literature survey reveals that several analytical methods have 
been reported for the quantification and determination of the drug 
individually in human plasma by liquid chromatography/tandem 
mass spectrometry.1,2,3,4,5
MATERIALS AND METHODS 
 It was found that no spectrophotometric 
method has been reported for the estimation of DRV. Hence, two 
simple, rapid, precise and accurate methods for the estimation of 
DRV in bulk and tablet dosage form is developed and validated. 
Materials 
DRV was generous gift samples from Ranbaxy Lab, Gurgaon. 
Commercial tablets with brand name, Daruvir (Cipla Ltd., Mumbai) 
containing 300mg was purchased from local market and used within 
their shelf-life period. All chemicals and solvents viz: methanol, used 
were of spectroscopy grade. 
 
Fig. 1: Structure of Darunavir ethanolate 
 
Instrumentation 
A Jasco double beam UV–visible spectrophotometer, Model: V-630, 
with a fixed bandwidth (2nm) and 1-cm quartz cell was used for 
Spectral and absorbance measurements. In addition, electronic 
balance, micropipette and sonicator were used in this study. 
Procedure 
Preparation of standard stock solution 
Standard stock solution of DRV was prepared separately by 
dissolving 25mg of drug in 25ml of methanol (spectroscopy grade) 
to get standard stock solution of 1000μg/ml by sonicating for 
15mins and 1ml was pipetted out and further volume was made up 
to 10ml with methanol to obtain concentration of 100μg/ml. 
Method A: Absorption Maxima Method  
For the selection of analytical wavelength, standard solution of DRV 
was scanned in the spectrum mode from 400 nm to 200 nm. From 
the spectra of drug [Fig.2], λmax of DRV, 266 nm was selected for the 
analysis. Aliquots of standard stock solution were made and 
calibration curve was prepared in the concentration range of 3-
18μg/ml [Fig.3], at 266nm.  
Method B: Area under Curve Method  
From the spectra of drug obtained after scanning of standard 
solution of DRV, area under the curve in the range of 255-275nm 
[Fig.4] was selected for the analysis. The calibration curve was 
prepared in the concentration range of 3-18μg/ml at their respective 
AUC range. The drug followed the Beer-Lambert’s law in the 
concentration range of 3-18μg/ml. The calibration curve was plotted 
as absorbance against concentration of DRV.  
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Fig. 2: λmax of DRV For the both methods (Absorption maxima 
method and AUC method), the coefficient of correlation (r), 
slope and intercept values are given in Table.1 
 
 
Fig. 3: Calibration curve of DRV 
 
Analysis of the marketed formulations 
Twenty tablets (Daruvir, Cipla Ltd., Mumbai) were taken and tablet 
weight equivalent to 300mg of DRV was weighed accurately and 
transferred to 100ml volumetric flask, dissolved in methanol with 
sonication and volume was made upto 100ml to get standard stock 
solution of 3000μg/ml. The solution was filtered through filter paper 
no. 41; 10 ml of this filtrate was further diluted to 100 ml of 
methanol. From this solution, further dilutions were made and the 
solution was scanned in the range of 200-400nm against blank. 
Absorbance was recorded at wavelength 266nm for method A and 
area was recorded in the range of 255 to 275nm for method B. 
Validation of UV method
The standard solutions were prepared by dilution of the stock 
solution with methanol to reach a concentration range. The 
absorbance was plotted against the corresponding concentrations to 
obtain the calibration curves. 
6 
Validation of the UV method was done with respect to following 
parameters. 
Linearity and Range  
 
Fig. 4: Area under curve of DRV 
  
Accuracy 
Recovery studies were carried out by applying the method to drug 
sample to which known amount of DRV corresponding to 80, 100, 
120% was added (standard addition method).  
Precision 
Precision of the method was verified by repeatability and 
intermediate precision studies. Repeatability studies (intra-day) 
were performed by analysis of DRV respectively on the same day. 
Intermediate precision (inter-day) of the method was checked by 
repeating analysis of DRV on three different days. Measurement of 
peak area for active compound was expressed in terms of % relative 
standard deviation (%R.S.D.). 
RESULTS AND DISCUSSION  
The methods discussed in the present work provide a convenient 
and accurate way for analysis of DRV in the tablet dosage form. 
Absorbance maxima of DRV at 266nm (Method A); Area Under 
Curve is measure in range of 255-275 (Method B) were selected for 
the analysis. Linearity for detector response was observed in the 
concentration range of 3-18μg/ml for the two methods.  
Percent label claim for DRV in tablet analysis was found in the range 
of 99.07 and 99.18 % respectively. Standard deviation and 
coefficient of variance for six determinations of tablet formulation, 
was found to be less than ± 2.0 indicating the precision of the 
methods. Accuracy of proposed methods was ascertained by 
recovery studies and the results are expressed as % recovery.  
Percent recovery for DRV was found in the range of 100.07 and 
99.58 values of standard deviation and coefficient of variation was 
satisfactorily low indicating the accuracy of all the methods. Percent 
RSD for Intraday assay precision was found to be 0.607 and 0.8847 
for Method A and B. Interday assay precision was found to be 0.587 
and 0.865 for Method A and B. Based on the results obtained, it is 
found that the proposed methods are accurate, precise, reproducible 
& economical and can be employed for routine quality control of 
DRV in bulk drug and its pharmaceutical dosage form.  
 
Table 1: Table shows Optical characteristics and precision. 
S. No. Parameter Method A Method B 
1 λ max/wavelength range(nm) 266 255-275 
2 Beer’s law limit (μg/ml) 3-18 (μg/ml) 3-18 (μg/ml) 
3 Molar absorptivity (L/mol.cm) 26187.015 480991.54 
4 Sandell’s sensitivity (μg/Sq.cm/0.001) 0.0209 0.0011 
5 Correlation coefficient (r ) 0.999 0.999 
6 Slope (m) 0.047 0.8782 
7 Intercept 0.003113 0.8873 
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Table 2: Table shows Results of Analysis of Tablet Formulation (N* 
Method 
=6) 
Label claim mg Amount of drug estimated (mg/tab) %Label claim* ± SD 
A 300 99.07 99.07±0.001 
B 300 99.18 99.18±0.04 
 
Table 3: Table shows Result of Recovery studies 
Excess drug added to the analyte (%)  % Recovery  %RSD  SE 
Method A Method B Method A Method B Method A Method B 
80 99.90 99.71 0.1858 0.1862 0.00156 0.02785 
100 100.16 99.75 0.0831 0.3181 0.00097 0.03025 
120 100.15 99.28 0.0832 0.3085 0.00063 0.03159 
RSD: a) Relative Standard deviation b) SE: Standard error  
 
Table 4: Table shows Result of Intra-day and Inter-day precision 
S. No. Intra-day Precision Inter-day Precision 
SD %RSD SE SD %RSD SE 
Method A 0.0017 0.6071 0.00072 0.0015 0.587 0.00069 
Method B 0.0480 0.8847 0.01960 0.0467 0.865 0.01897 
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